A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook
AbbVie (ABBV) is back in focus after presenting fresh real world and long term data for its key immunology drugs SKYRIZI and RINVOQ at the 2026 Digestive Disease Week meeting. See our latest analysis for AbbVie. Those fresh immunology data and a string of recent conference appearances come as AbbVie’s share price has eased this year, with a year to date share price return of down 9.35%, even though the 1 year total shareholder return is 14.17% and the 5 year total shareholder return is...